5 Key Takeaways

• 1

  The FDA approved tirzepatide to reduce major cardiovascular event risk in adults with type 2 diabetes at high risk.

• 2

  The approval includes reducing the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

• 3

  The indication was based on the SURPASS-CVOT trial, which involved 13,299 participants with type 2 diabetes.

• 4

  Tirzepatide was found noninferior to dulaglutide for major adverse cardiovascular events over a median follow-up of 4 years.

• 5

  Common adverse events with tirzepatide included gastrointestinal issues, generally mild to moderate in severity.